Remdesivir for the treatment of COVID-19

Austrian Institute for Health Technology Assessment (AIHTA)
Record ID 32018001151
Authors' objectives: In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of COVID-19. This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative Review – PTRCR15, published in September 2020, evidence gaps were identified, such as the need for adequately powered RCTs with clinically relevant outcomes, including all-cause mortality, the additional need for and duration of mechanical ventilation, additional need for and duration of supplemental oxygen and duration of hospitalisation. The subsequent publication of results from two RCTs, including the final report of the ACTT-1 trial and the preliminary report of the WHO SOLIDARITY trial, as well as data from two living clinical guidelines, are used to summarise the most recent evidence to further support the local production of national/regional HTA reports.
Project Status: Completed
Year Published: 2020
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
MeSH Terms
  • COVID-19
  • Coronavirus Infections
  • SARS-CoV-2
  • Adenosine Monophosphate
  • Alanine
  • Drug Therapy
  • Antiviral Agents
Organisation Name: European Network for Health Technology Assessment
Contact Email:
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.